Introduction
============

Oral contraceptives (OCs) have proved to be a popular method of contraception with \>100 million women estimated to use them worldwide, since their introduction in the 1960s.[@b1-ijwh-8-477]

Despite being one of the most effective forms of contraception and there being an ever-widening choice of OCs to suit the individual needs of women, a high percentage of users discontinue OCs for various reasons, leading to an increased risk of unintended pregnancy, if not replaced by a comparably effective method.[@b2-ijwh-8-477]

Indeed, prospective survey data have shown that four-fifths of women who stopped OCs subsequently failed to adopt another method or chose a less effective form of contraception.[@b2-ijwh-8-477],[@b3-ijwh-8-477] Other studies have found that there is a high rate of discontinuation within the first 1--2 years of OC use and that method-related reasons, notably the occurrence of side effects such as bleeding irregularities, were the most commonly cited causes.[@b3-ijwh-8-477],[@b4-ijwh-8-477]

Progestogen-only pills (POPs) in particular are associated with problematic (unscheduled) bleeding, a common reason for discontinuation in up to 25% of users, that can affect adherence.[@b5-ijwh-8-477],[@b6-ijwh-8-477] Rates of discontinuation with POPs have been noted to vary according to the progestogen content,[@b7-ijwh-8-477],[@b8-ijwh-8-477] although a recent review found that there were insufficient data to compare POPs with each other or with combined OCs (COCs).[@b8-ijwh-8-477]

Lower rates of discontinuation have been observed with COCs than with POPs, with an inverse relationship to the dose of ethinylestradiol (EE) used.[@b4-ijwh-8-477] The results of a Cochrane review[@b9-ijwh-8-477] found that discontinuation rates were higher for OCs containing very low doses of EE compared with higher-dose estrogen preparations.

In a European clinical trial,[@b10-ijwh-8-477] a COC containing estradiol valerate and dienogest (E~2~V/DNG) in a dynamic dosing regimen (Qlaira^®^/Natazia™; Bayer AG, Leverkusen, Germany) reported that only 2.5% of women discontinued treatment prematurely due to bleeding irregularities.

Although it is now well known that most women using POPs stop their pill for method-related reasons within the first year of use, there is limited information on continuation rates due to user acceptability of bleeding profile changes and overall satisfaction with the E~2~V/DNG pill in a real-life setting. As bleeding patterns may influence continuation rates more typically in POP use, E~2~V/DNG users were compared with POP users to assess the acceptability of the bleeding profile, the continuation rates, and user satisfaction. The CONTENT study ([ClinicalTrials.gov](http://ClinicalTrials.gov) identifier: NCT01200186) was specifically designed to look at these parameters in the first year of use of the E~2~V/DNG pill, compared with a POP, after switching from a COC-containing EE.

Methods
=======

Study design and participants
-----------------------------

CONTENT was a Phase IV, prospective, multicenter, noninterventional, observational study in women (aged 18--50 years) switching from an EE-containing OC pill to the E~2~V/DNG pill or a POP. The study was conducted at 375 investigational sites in eleven countries: the Czech Republic, France, Germany, Greece, Hungary, Israel, Italy, the Russian Federation, Slovakia, Sweden, and the UK. Approval by independent ethics committees or institutional review boards was obtained in each country where required ([Table S1](#SD2-ijwh-8-477){ref-type="supplementary-material"}). All patients provided written informed consent.

For inclusion, women must have been using EE-containing OCs for ≥3 months prior to enrollment and must have decided to switch either to the E~2~V/DNG pill or to a POP, depending on individual choice. Exclusion criteria were in accordance with the contraindications, precautions, and warnings for women receiving the E~2~V/DNG pill or chosen POP based on the approved product labeling in each country. Women who were breastfeeding were also excluded.

The E~2~V/DNG pill was administered via a dynamic dosing regimen (E~2~V 3 mg on days 1 and 2, E~2~V 2 mg/DNG 2 mg on days 3--7, E~2~V 2 mg/DNG 3 mg on days 8--24, E~2~V 1 mg on days 25--26, and placebo on days 27--28). The chosen POP was administered according to the relevant prescribing information. As this is a noninterventional study, the duration of treatment was at the discretion of the physician. Women were followed for 1 year.

Assessment and study outcomes
-----------------------------

The overall aim was to assess continuation rates and user acceptability of any bleeding changes and satisfaction with the E~2~V/DNG pill and selected POPs in a real-life setting.

Women taking an EE-containing pill were assessed before they decided to switch to the E~2~V/DNG pill or to a POP (visit 1). At this initial screening visit, the medical, surgical, and gynecological history (including age at menarche and reproductive history), previous POP experience and reasons for stopping the current pill were recorded. Bleeding patterns during the preceding 3 months were evaluated, with repeat assessment at 3--5 months (visit 2) and again at 6--12 months (visit 3).

The primary outcome assessment was the time to discontinuation due to unacceptable bleeding during the first year of use, and the main secondary outcome measure was the time to discontinuation for other reasons. Other secondary outcomes included the cumulative discontinuation rate according to bleeding regularity (ie, unscheduled, infrequent, or absent), intensity (ie, heavy and/or prolonged), and the presence of pain in association with bleeding. Other medical reasons (eg, adverse event \[AE\], change in medical eligibility) and nonmedical reasons (eg, study consent withdrawn, poor adherence) for discontinuation were recorded.

At visits 2 and 3, women self-assessed their satisfaction and well-being using a five-point category scale (1= much worse to 5= much better, compared with baseline). AEs were carefully assessed and recorded, whether or not related to the use of either pill.

Statistical analyses
--------------------

Sample size was selected based on an assumed discontinuation rate of 5% for the E~2~V/DNG pill and 10% for POP at 1 year. Assuming a significance level of 5% (two-sided log-rank test) and a power of 90%, \~600 patients had to be enrolled per treatment group for a 1:1 allocation. However, in the real-life setting of a noninterventional study, the allocation ratio cannot be stipulated. The ratio of women in each group (E~2~V/DNG:POP) of 1:4 to 4:1 was dependent on utilization of each contraceptive pill across centers. For the sample size calculation, a ratio of 1:1 was assumed for the calculation of the size of the smaller treatment group. This approach led to a total sample size of 3,000 patients and allowed a power of at least 90% for all allocation ratios.

Time-to-event for discontinuation due to unacceptable bleeding or due to other reasons was calculated and analyzed by means of the Kaplan--Meier estimator. Time until discontinuation was censored at the end of observation, if no discontinuation was reported until the end of observation.

Treatment groups were compared based on a proportional hazard model, and propensity score methods (as detailed in the Supplementary materials) were applied by an outcome-blinded third party (Stat-Epi Associates, Inc., South Ponte Vedra Beach, FL, USA) to account for allocation bias and possible confounding factors.

Descriptive analysis of the data, including user satisfaction and well-being, was performed using basic summary statistics. Continuous data were described by median, mean, standard deviation, minimum, maximum, and 25 and 75 percentiles. Categorical data, including categories of continuous data, were presented in frequency tables. The number of participants with missing data was presented as a separate category.

The primary and secondary outcomes were analyzed for all women. Safety analyses were conducted for all women who took at least one dose of the study drug (defined as safety population).

Results
=======

Of a total of 3,258 women who were enrolled, 3,152 women had data available for efficacy assessment and 3,237 formed the safety population. Of these, 2,558 (81.2%) and 2,629 (81.2%) in each group received the E~2~V/DNG pill and 592 (18.8%) and 605 (18.7%) received a POP. For two women in the efficacy population and three in the safety population, the treatment could not be defined, and therefore their data were not analyzed in detail. The majority (\>80%) of POPs used by women participating in the study contained desogestrel.

Except for participants' smoking status, there were no relevant differences between the two study groups in terms of their demographic data ([Table 1](#t1-ijwh-8-477){ref-type="table"}).

Both study groups were also well balanced in terms of the bleeding pattern at baseline ([Table S2](#SD3-ijwh-8-477){ref-type="supplementary-material"}). In the 3 months prior to discontinuing their EE-containing pill, the majority (85%) of women experienced regular bleeds in both the E~2~V/DNG and POP groups, with \~13% experiencing occasional or absent bleeding and 1%--2% amenorrhea. The minimum duration of bleeding, maximum intensity of bleeding, and percentage of women with painful or intracyclic bleeding were also comparable at baseline.

Reasons for discontinuing the prior EE-containing pill and switching to either the E~2~V/DNG pill or to a POP differed between the two groups. The most common reasons given by participants who switched to the E~2~V/DNG pill were that they "want to try something else" (36.6%), received a "recommendation" (34.2%) from a health care provider, or had experienced "side effects (other than bleeding-related)" (24.0%). In women who switched to a POP, the most common reasons given for subsequent discontinuation of the method were "side effects (other than bleeding-related)" (23.5%), "contraindications" (22.5%), "smoking" (21.3%), and that they had received a "recommendation" (20.9%) to do so.

Continuation of contraception
-----------------------------

A total of 659 (20.9%) women discontinued their prescribed pill during the course of the study or at the end of study visit; 19.8% of women (n=506) in the E~2~V/DNG group versus 25.8% of women (n=153) in the POP group ([Figure 1](#f1-ijwh-8-477){ref-type="fig"}). The median time until discontinuation (due to any reason) was 157.0 days in the E~2~V/DNG group and 127.5 days in the POP group.

Kaplan--Meier and Cox regression analysis showed that the time to discontinuation was significantly longer in the E~2~V/DNG group than in the POP group due to bleeding (*P*\<0.0001) or other reasons (*P*=0.022).

Propensity score-adjusted analysis to account for confounding by stratified Cox regression showed significant differences between the groups (*P*=0.0004 and *P*=0.0244, respectively), indicating a significant treatment effect on the primary outcome.

Reasons for discontinuation
---------------------------

The most frequent reasons for discontinuation of the E~2~V/DNG pill during the first year of use after switching from an EE-containing COC were nonmedical (44.3%) followed by unacceptable bleeding pattern (27.7%). Conversely, in the women switching to a POP, unacceptable bleeding patterns (37.9%) followed by nonmedical (31.4%) and then medical reasons (30.1%) were the most common reasons for discontinuation. In approximately half of the patients who indicated nonmedical reasons, the wish to conceive was the most frequently given reason in both the E~2~V/DNG and POP groups (47.8% vs 58.3%, respectively) followed by accessibility/cost (32.6% vs 18.8%).

Women who indicated medical reasons for discontinuation stated AEs most frequently in both the E~2~V/DNG and POP groups (84.3% and 87.0%, respectively). When unacceptable bleeding pattern was the reason, intracyclic bleeding (ie, more than once per month bleeding) was most frequently recorded in both groups (75.7% and 77.6%, respectively).

Effect on the bleeding profile
------------------------------

### Regularity of bleeding

The E~2~V/DNG pill was superior at maintaining a regular bleeding pattern ([Figure 2A](#f2-ijwh-8-477){ref-type="fig"}) in women switching from an EE-containing pill to either E~2~V/DNG or to a POP. The proportion of women in the E~2~V/DNG and POP groups with occasionally absent withdrawal bleeding was 13.7% in the E~2~V/DNG group and 12.7% in the POP group at baseline, increasing to 24.3% and 31.1% at the last visit in each group, respectively. Corresponding values for amenorrhea were 1.0% and 2.2% at baseline and 8.2% and 43.5% at the last visit.

Bleeding regularity was influenced by age, with women aged 35--50 years having less regular bleeding than women aged 18--34 years.

### Duration of bleeding

The maximum length of bleeding decreased considerably during the study, as indicated by the increasing proportion of women with maximum length of bleeding for only 1--2 days (E~2~V/DNG group: 9.5% at baseline to 48.7% at last visit; POP group: 10.9% at baseline to 44.1% at last visit). The proportions of women bleeding for 3--5 days, 6--7 days, and ≥8 days at baseline and last visit in the E~2~V/DNG and POP groups were 65.4%/45.5%, 20.7%/3.1%, and 4.2%/2.5% and 69.6%/34.9%, 15.9%/10.5%, and 3.3%/10.5%, respectively. Changes from baseline to last visit in length of bleeding are shown in [Figure 2B](#f2-ijwh-8-477){ref-type="fig"}.

### Intensity of bleeding

The maximum intensity of bleeding decreased considerably from baseline with both pills, with an increasing proportion of women describing their periods as "light/scanty" at the last visit (E~2~V/DNG group: 21.4% at baseline to 54.0% at last visit; POP group: 24.2% at baseline to 46.1% at last visit). The proportion of women with "normal" intensity bleeding decreased from 55.3% at baseline to 18.3% at last visit in the E~2~V/DNG group and from 52.9% to 15.1% in the POP group. The proportion of women with heavy bleeding was also reduced from 16.3% to 1.6% in the E~2~V/DNG group and from 15.4% to 4.3% in the POP group ([Figure 2C](#f2-ijwh-8-477){ref-type="fig"}).

### Dysmenorrhea

The proportion of women with painless bleeding increased from 71.3% to 91.1% in the E~2~V/DNG group versus no change in the POP group (74.7% at baseline and 73.7% at the last visit; [Figure 2D](#f2-ijwh-8-477){ref-type="fig"}).

### Problematic (unscheduled) bleeding

The proportion of women experiencing problematic bleeding did not change considerably from baseline to last visit in the E~2~V/DNG group, although a slight decrease was noted compared with an increase seen in the POP group.

User satisfaction with their pill
---------------------------------

Switching to an E~2~V/DNG pill was associated with a higher degree of user satisfaction than switching to a POP after only 3--5 months (visit 2), irrespective of age ([Figure 3](#f3-ijwh-8-477){ref-type="fig"}). In addition, the proportion of patients who felt "indifferent" was higher in the POP group than in the E~2~V/DNG group, and the proportion of women discontinuing their pill due to dissatisfaction was also higher in the POP group throughout the study.

Physical and emotional well-being
---------------------------------

User-reported physical well-being was reported as "better" or "much better" by 75.7% of women taking the E~2~V/DNG pill versus 63.0% of those taking a POP by the time of the last visit. A higher proportion of women in the E~2~V/DNG group also reported feeling emotionally "better" or "much better" (71.8% vs 56.7%) by their last visit than those in the POP group ([Figure S1](#SD1-ijwh-8-477){ref-type="supplementary-material"}).

Contraceptive efficacy
----------------------

Both treatments were highly effective with only two pregnancies in users of the E~2~V/DNG pill and one in the POP group recorded during the study period.

Safety and tolerability
-----------------------

Both the E~2~V/DNG pill and POP were generally well tolerated. The overall rates of all treatment-emergent AEs (TEAEs) were 7.4% (n=194) and 11.2% (n=68), respectively. Incidences of drug-related and serious TEAEs were 5.0%, and 9.3%, 0.1%, and 0.0, for E~2~V/DNG and POP, respectively; drug-related TEAEs resulting in permanent discontinuation of the study pill were 5.0% and 7.8% ([Table S3](#SD4-ijwh-8-477){ref-type="supplementary-material"}). The most frequently documented, drug-related TEAEs in the E~2~V/DNG group were headache (1.14%), acne (0.65%), weight increase (0.53%), and breast pain (0.49%). In the POP group, the most frequent drug-related TEAEs were acne (2.64%), metrorrhagia (1.16%), weight increase (0.99%), and breast pain (0.99%).

Discussion
==========

CONTENT is a large-scale study undertaken to evaluate women's experience of using the E~2~V/DNG pill versus a POP in a real-life setting. Specifically, the study was designed to compare continuation rates, bleeding profile acceptability, and user satisfaction during the first year of use of either pill after switching from an EE-containing pill.

Results showed that switching to the E~2~V/DNG pill led to a higher continuation rate and significantly longer continuation time than switching to a POP. Furthermore, user satisfaction and well-being were also rated higher in women switching to the E~2~V/DNG pill compared with a POP.

Reasons for the better continuation and satisfaction with the E~2~V/DNG pill versus the POP may be attributed to the different bleeding profiles seen with each pill. Both pills reduced the length and intensity of bleeding and increased the rate of absent withdrawal bleeding. The incidence of painful bleeding was reduced in patients after switching to E~2~V/DNG, whereas there was no change from baseline in the POP group. It should be noted that \~70% of all patients had no painful bleeding at baseline. Given that all patients had switched from a COC, painless bleeding could be a class effect with all COCs, with a more pronounced effect seen with E~2~V/DNG.

Although the majority of women did not experience problematic bleeding, a slight decrease from baseline (5.1%) was seen in women taking the E~2~V/DNG pill compared with a slight increase of 5.9% in the POP group. Problematic (unscheduled) bleeding was originally intended to be assessed only in women who reported withdrawal bleeding. However, this was not clear from the case report form and therefore women in the POP group experiencing no withdrawal bleeding would not have been able to answer the question and their data would have been marked as "missing" and could account for the differences observed.

The E~2~V/DNG pill combines estradiol with dienogest in a multiphasic regimen with a shortened hormone-free interval[@b11-ijwh-8-477] and leads to stable estradiol levels throughout the whole cycle.[@b12-ijwh-8-477] This may account for the better overall outcomes seen in this study with the E~2~V/DNG pill when compared with POP use.

In studies examining the effects of E~2~V/DNG versus either EE/norgestimate[@b13-ijwh-8-477] or EE/levonorgestrel[@b14-ijwh-8-477] on hormone withdrawal-associated symptoms, the shortened hormone-free interval and stable estradiol levels associated with the E~2~V/DNG pill led to a decrease in hormone withdrawal-associated symptoms, such as headache and pelvic pain. Further findings from a study looking at the effects of E~2~V/DNG versus EE/levonorgestrel[@b15-ijwh-8-477] on dysmenorrheic pain demonstrated a significant reduction in dysmenorrhea. The benefits of the E~2~V/DNG pill on the bleeding pattern have also been observed in women suffering from heavy menstrual bleeding,[@b16-ijwh-8-477] and the E~2~V/DNG pill is the only COC indicated for treatment of this condition/indication. Heavy menstrual bleeding was noted in a proportion of patients entering this study. The E~2~V/DNG pill has also been shown to improve symptoms of COC-associated female sexual dysfunction, which is often impaired with the intake of other COCs.[@b17-ijwh-8-477]

As this was a real-life setting, the study population of CONTENT was more heterogeneous than that seen in a randomized, controlled trial. For this reason, propensity score adjustment was used to help reduce the effect of allocation bias or confounding variables on the estimation of treatment effect. It is acknowledged that such methods cannot guarantee that all effects of confounders are eliminated and the effects of unmeasured confounders cannot be discounted, which may be considered a limitation of the present study. The fact that the study did not include a placebo arm or an active comparator arm means that the degree to which the results reflect drug-specific effects remains uncertain. Nevertheless, a number of randomized, controlled trials have been published, which have answered such research questions sufficiently, and the results of the CONTENT study are in accordance with the findings of the previous randomized studies involving the E~2~V/DNG pill[@b13-ijwh-8-477]--[@b17-ijwh-8-477] and POPs.[@b7-ijwh-8-477]--[@b9-ijwh-8-477]

Conclusion
==========

Switching to the E~2~V/DNG pill resulted in a higher continuation rate and significantly increased continuation time than switching to a POP, with more women wanting to continue with the E~2~V/DNG pill than with the POP at the end of the observational study. This was confirmed by propensity score adjustment of treated patients to account for confounding variables, which showed significant differences between the two groups at baseline.

Generally, women who switched from an EE-containing COC to the E~2~V/DNG pill or to a POP had shorter, lighter, and more frequent absence of withdrawal bleeding. Additionally, in comparison to those receiving POP, women taking the E~2~V/DNG pill experienced less painful bleeding as well as less problematic (unscheduled) bleeding. Switching to the E~2~V/DNG pill was also associated with a higher degree of user satisfaction with around three-quarters of women expressing high satisfaction in addition to better physical and emotional well-being.

Both the E~2~V/DNG pill and POP were well tolerated, with low discontinuation rates due to AEs. The event pattern and the intensity of the TEAEs reported in this study were in line with the established safety profile of the E~2~V/DNG pill and POPs.

Overall, the CONTENT study shows that switching to the E~2~V/DNG pill can result in higher continuation rates and high user acceptability and satisfaction in the real-life setting when compared with a POP. The E~2~V/DNG pill may be an alternative option for women who are dissatisfied with their current pill.

Supplementary materials
=======================

Propensity score methodology
----------------------------

Propensity score methods (based on Austin[@b18-ijwh-8-477]) were applied by an outcome-blinded third party (Stat-Epi Associates, Inc.) to account for allocation bias and possible confounding factors.

This method allowed for hypothetical randomization. Propensity score was estimated for each patient, using a logistic regression model, with treatment group indicator as the dependent variable and pretreatment baseline characteristics (including age, reason for discontinuation of EE-containing OCs, important medical history, such as thrombotic diseases, and bleeding pattern during preceding 3 months) as independent variables. The fitted values from the logistic regression yielded the estimated propensity scores, such that each score summarized an individual patient's pretreatment covariates. In order to balance covariates across the two treatment groups and allow unbiased estimation of the treatment effect, ten subclasses were created comprising patients who had similar estimated propensity score. These subclasses were then analyzed as if the study had been a stratified randomized experiment using a stratified Cox regression model.

Study approval and reviewing boards
-----------------------------------

Study approval was obtained by independent ethics committees or institutional review boards in each country where required ([Table S1](#SD2-ijwh-8-477){ref-type="supplementary-material"}).

Bleeding pattern at baseline
----------------------------

Both study groups were well balanced in terms of the bleeding pattern at baseline, shown in [Table S2](#SD3-ijwh-8-477){ref-type="supplementary-material"}.

Emotional and physical well-being
---------------------------------

User-reported physical well-being and emotional well-being are depicted in [Figure S1](#SD1-ijwh-8-477){ref-type="supplementary-material"}.

Safety and tolerability
-----------------------

Both the E~2~V/DNG pill and POP were generally well tolerated. The overall rates of all treatment-emergent adverse events (TEAEs) for E~2~V/DNG pill or POP are shown in [Table S3](#SD4-ijwh-8-477){ref-type="supplementary-material"}.

###### 

Percentage of women who rated their (**A**) physical or (**B**) emotional well-being as "better" or "much better" at their last visit after switching to the E~2~V/DNG pill or POP.

**Abbreviations:** E~2~V/DNG, estradiol valerate and dienogest; POP, progestogen-only pill.

###### 

Ethics committees and institutional review boards that approved the study

  Country                                                                                   Reviewing board
  ----------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------
  Czech Republic                                                                            • State Institute for Drug Control (SUKL)
  France                                                                                    • Conseil Nacional de l'Ordre des Medicines
  Germany                                                                                   • Bundesinstitut für Arzneimittel und Medizinprodukte
  • GKV: Spitzenverband                                                                     
  • KBV Kassenärztliche Bundesvereinigung                                                   
  Greece                                                                                    • National Drug Organization
  • General Hospital of Thessaloniki "PAPAGEORGIOU". Hospital Scientific Committee          
  Hungary                                                                                   • EGÉSZSÉGÜGYI TUDOMÁNYOS TANÁCS - Medical Research Council Scientific and Research Committee
  Israel                                                                                    • EC: Maccabi Healthcare
  Italy                                                                                     • EC: Azienda Ospebaliera Universitaria Policlinio Paolo Giaccone die Palermo
  • EC: Umberto I Policlinico die Roma                                                      
  • EC: Azienda Ospedaliero Universitaria, Santa Maria de la Misericordia di Udine          
  • EC: Azienda Ospedaliero die Rilievo Nazionale e die alta Specializzazione "Garibaldi"   
  • EC: Universita di ferra, Servicio sanitario regionale Emilia Ramagna                    
  • EC: Universitaria degli Studi die Napoli "FedericoII"                                   
  • EC: Azienda Ospedaliero, San Gerardo                                                    
  Russia                                                                                    • EC: Interuniversity ethic committee
  • Ministry of Health                                                                      
  Slovakia                                                                                  • SAFS: Slovenská asociácia farmaceutických spoločností orientovaných na výskum a vývoj
  • State Institute for Drug Control SUKL                                                   
  • EC: Ustredna Eticka komisia Bratislaveskeho samospravneho kraja                         
  Sweden                                                                                    • EC: Regionala etikprövningsnämnden i Uppsala
  • Medical Product agency                                                                  
  Great Britain                                                                             • National Research Ethics Service
  • Sussex NHS Research Consortium                                                          
  • NHS Berkshire East                                                                      
  • NHS Leeds                                                                               
  • Liverpool NHS                                                                           
  • NHS: Comprehensive Local Research Network for Kent and Medway                           
  • NHS York Hospitals                                                                      

###### 

Bleeding pattern during the preceding 3 months before enrollment (baseline visit, efficacy population)

  Bleeding pattern parameters                     Total (N=3,150)   E~2~ V/DNG (n=2,558)   POP (n=592)                
  ----------------------------------------------- ----------------- ---------------------- ------------- ------ ----- ------
  Regularity of withdrawal bleeding                                                                                   
   Regular (once a month)                         2,680             85.1                   2,177         85.1   503   85.0
   Occasionally absent                            426               13.5                   351           13.7   75    12.7
   Amenorrhea                                     38                1.2                    25            1.0    13    2.2
  Maximum length of bleeding (days)                                                                                   
   1--2                                           302               9.7                    239           9.5    63    10.9
   3--5                                           2,055             66.2                   1,653         65.4   402   69.6
   6--7                                           615               19.8                   523           20.7   92    15.9
    ≥8                                            126               4.1                    107           4.2    19    3.3
  Maximum intensity of bleeding                                                                                       
   Spotting                                       205               6.6                    164           6.5    41    7.1
   Light/scanty                                   681               21.9                   541           21.4   140   24.2
   Normal                                         1,703             54.8                   1,397         55.3   306   52.9
   Heavy                                          500               16.1                   411           16.3   89    15.4
  Painful bleeding                                                                                                    
   Yes                                            2,265             71.9                   1,823         71.3   442   74.7
   No                                             864               27.4                   720           28.1   144   24.3
  Intracyclic bleeding (more than once a month)                                                                       
   Yes                                            2,676             85.0                   2,157         84.3   519   87.7
   No                                             454               14.4                   386           15.1   68    11.5

**Abbreviations:** E~2~V/DNG, estradiol valerate and dienogest; POP, progestogen-only pill.

###### 

Overview of TEAEs associated with E~2~V/DNG and POP use

  Type of event                 Total (N=3,234)   E~2~ V/DNG (n=2,629)   POP (n=605)              
  ----------------------------- ----------------- ---------------------- ------------- ----- ---- ------
  Overall adverse event rate    262               8.1                    194           7.4   68   11.2
  Drug-related adverse events   188               5.8                    132           5.0   56   9.3
  Serious adverse events                                                                          
   Nondrug related              3                 0.1                    3             0.1   0    0.0
   Drug related                 3                 0.1                    3             0.1   0    0.0
   Deaths                       0                 0.0                    0             0.0   0    0.0
  Discontinuation                                                                                 
   Nondrug related              179               5.5                    132           5.0   47   7.8
   Drug related                 145               4.5                    102           3.9   43   7.1

**Abbreviations:** E~2~V/DNG, estradiol valerate and dienogest; POP, progestogen-only pill; TEAEs, treatment-emergent adverse events.
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![Kaplan--Meier plot of duration until discontinuation due to unacceptable bleeding or other reasons (propensity score-adjusted population analysis).\
**Note:** \*Time to discontinuation for E~2~V/DNG vs POP.\
**Abbreviations:** E~2~V/DNG, estradiol valerate and dienogest; POP, progestogen-only pill.](ijwh-8-477Fig1){#f1-ijwh-8-477}

![Bleeding profile changes at baseline and the last visit after switching to the E~2~V/DNG pill or POP.\
**Notes:** Proportion of women with (**A**) regular bleeding (once a month); (**B**) change from baseline in length of bleeding; (**C**) light/scanty bleeding; and (**D**) painless bleeding.\
**Abbreviations:** E~2~V/DNG, estradiol valerate and dienogest; POP, progestogen-only pill.](ijwh-8-477Fig2){#f2-ijwh-8-477}

![Percentage of women who rated their overall satisfaction as "satisfied" or "very satisfied" 3--5 months after switching to the E~2~V/DNG pill or POP.\
**Abbreviations:** E~2~V/DNG, estradiol valerate and dienogest; POP, progestogen-only pill.](ijwh-8-477Fig3){#f3-ijwh-8-477}

###### 

Baseline demographic characteristics

  -------------------------------------------------------------------------------------
  Variable                      Total\      E~2~ V/DNG\   POP\                   
                                (N=3,150)   (n=2,558)     (n=592)                
  ----------------------------- ----------- ------------- --------- ------ ----- ------
  Age (years)                                                                    

   18--25                       706         22.4          572       22.4   134   22.6

   26--34                       1,034       32.8          850       33.2   184   31.1

   35--50                       1,215       38.6          994       38.9   221   37.3

  BMI (mg/kg^2^)                                                                 

   \<18.5                       169         5.4           141       5.5    28    4.7

   18.5 to \<25                 2,281       72.4          1,872     73.2   409   69.1

   26 to \<30                   492         15.6          398       15.6   94    15.9

   \>30                         144         4.5           102       4.0    42    7.1

  Educational level                                                              

   Primary school               85          2.7           60        2.3    25    4.2

   Higher than primary school   3,046       96.7          2,483     97.1   563   95.1

  Smoking status                                                                 

   No                           2,543       80.7          2,129     83.2   414   69.6

   Yes                          607         19.3          429       16.8   178   30.1
  -------------------------------------------------------------------------------------

**Abbreviations:** BMI, body mass index; E~2~V/DNG, estradiol valerate and dienogest; POP, progestogen-only pill.
